Cipla's Yurpeak Expands in India as Biocon Sees Potential in Generic Liraglutide Markets

Cipla's tirzepatide brand Yurpeak has rapidly gained market share in India since its December 2025 launch, expanding beyond major metros into tier 2 and 3 cities with Rs 18.8 crore sales in January 2026. Meanwhile, Biocon's CEO Siddharth Mittal highlighted that despite price cuts by innovators like Novo Nordisk, the generic liraglutide market remains viable, especially in the US and Europe, though overall volumes are not expected to grow due to shifts toward newer therapies like semaglutide and Mounjaro.